---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000030"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-10-13T12:25:13+00:00"
generated_at: "2026-10-13T12:30:03.328428+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# iBio's IBIO-610 plus semaglutide cut lean-mass share of NHP weight loss to 6% vs 22%

## Summary
- In an 8-week obese NHP study (n=6 per group), fat was 93% of weight lost with single-dose IBIO-610 plus twice-weekly semaglutide, vs 77% with semaglutide alone.
- Lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone.
- IBIO-610 produced 97% reduction in active Activin E serum levels at week 8 after a single IV dose; NHP half-life was 33.2 days, potentially supporting twice-yearly human dosing.
- Data presented in an oral session at the EASD Annual Meeting on Oct. 1, 2026; iBio plans to start first-in-human trials of IBIO-610 in the first half of 2027.
- CEO/CSO Martin Brenner framed IBIO-610 as addressing the quality-of-weight-loss gap left by GLP-1 therapies; all results are preclinical.

## SEC filing metadata
- accession: 0001420720-26-000030
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-10-13T12:25:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/0001420720-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000030/ibio-20261013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000030
- JSON: https://secwatch.observer/filing/0001420720-26-000030.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.